Af­ter tak­ing a hard look at the da­ta, No­var­tis punts Aduro’s STING drug — the lat­est in a long line of set­backs

Things keep get­ting worse at the be­lea­guered Aduro.

Stephen Isaacs

Ten months af­ter CEO Stephen Isaacs was forced to re­struc­ture and down­size the staff af­ter a se­ries of set­backs, No­var­tis is dump­ing Aduro’s lead sur­viv­ing drug af­ter con­clud­ing from the clin­i­cal da­ta that there was no rea­son to push for­ward.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.